Physician

Rakesh C. Patel, DO

According to 2025 Medicare claims, Rakesh Patel, DO (NPI: 1295712305) practices rheumatology in the Charlotte-Concord-Gastonia, NC-SC market, with the plurality of this provider's patient population coming from Rowan, NC. This provider's primary affiliated billing organization is ROWAN DIAGNOSTIC CLINIC P.A. (NPI: 1477582120; TIN: 560988429) and primary practice location at 28144-2567. Patel is affiliated with the Aledade A4548 NC Legacy MSSP Enhanced (ACO ID: A4548), participating under the MSSP model.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 172 traditional Medicare patients, billed 70,300 HCPCS/CPT codes, and received $893,278 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,213 prescription claims across 447 beneficiaries totaling $3,692,479 in drug costs, led by Enbrel Mini (Etanercept). Open Payments data shows 215 records totaling $325,431. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $685,780 to $893,278. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,195,541 to $3,692,479. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	282	55,706	$685,780
2016	209	47,979	$674,346
2017	228	59,551	$743,884
2018	273	79,998	$1,018,123
2019	249	84,100	$999,788
2020	204	78,637	$855,353
2021	229	72,009	$910,698
2022	181	69,961	$1,302,067
2023	177	62,660	$1,303,321
2024	172	70,300	$893,278

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	299	3,194	$1,195,541
2016	297	3,175	$1,276,688
2017	316	3,243	$1,565,988
2018	375	3,561	$1,647,109
2019	367	3,578	$2,050,963
2020	342	3,454	$2,524,221
2021	334	3,019	$2,714,466
2022	346	3,115	$2,337,707
2023	397	3,600	$3,155,504
2024	447	4,213	$3,692,479

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	64	89	$114
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	146	403	$87
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	114	211	$11
96372	Injection of drug or substance under skin or into muscle	50	111	$10
J7050	Infusion, normal saline solution, 250 cc	39	318	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Mini	Etanercept	188	5,276	$1,392,492
Rinvoq	Upadacitinib	100	3,240	$690,209
Kevzara	Sarilumab	73	2,064	$308,667
Orencia Clickject	Abatacept	50	1,400	$280,142
Humira(Cf) Pen	Adalimumab	22	616	$145,493

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	145	$3,679	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	70	$321,752	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rakesh C. Patel, DO?

Tedicare shows public-source Medicare data for Rakesh C. Patel, DO (NPI 1295712305), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rakesh C. Patel, DO have ACO affiliation data?

Rakesh C. Patel, DO is shown with ACO affiliation data for Aledade A4548 NC Legacy MSSP Enhanced (MSSP, ACO ID A4548).

What billing organization is linked to Rakesh C. Patel, DO?

Rakesh C. Patel, DO is linked to ROWAN DIAGNOSTIC CLINIC P.A. (billing NPI 1477582120) in the available physician profile data.

Does Rakesh C. Patel, DO have Open Payments data?

Rakesh C. Patel, DO has 215 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.